Added to YB: 2024-09-17
Pitch date: 2024-09-10
NTRA [bullish]
Natera, Inc.
+72.46%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
Market Cap
$28.8B
Pitch Price
$118.79
Price Target
N/A
Dividend
N/A
EV/EBITDA
-111.11
P/E
-133.35
EV/Sales
12.10
Sector
Biotechnology
Category
growth
Show full summary:
Brown Capital Management Mid Company Fund Portfolio Holding: Natera, Inc.
NTRA: Diagnostic co using advanced DNA detection in blood tests. Leader in prenatal, cancer recurrence & transplant rejection tests. 25% rev to R&D. $15-20B cancer market opportunity. Unprofitable now but scaling & improving reimbursements. 20% 5yr rev CAGR expected. Large markets, innovation & clinical data support growth.
Read full article (1 min)